visual fluorescence-observation cell-binding assay ca1128-0502 (EUROIMMUN)
90
Structured Review
EUROIMMUN
visual fluorescence-observation cell-binding assay ca1128-0502
Visual Fluorescence Observation Cell Binding Assay Ca1128 0502, supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/visual+fluorescence-observation+cell+binding+assay/visual+fluorescence+observation+cell+binding+assay+ca1128+0502/10__1016_slash_s1474___4422_ascii40_24_ascii41_00077___2-81-29-30
Average 90 stars, based on 1 article reviews
Visual Fluorescence Observation Cell Binding Assay Ca1128 0502, supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/visual+fluorescence-observation+cell+binding+assay/visual+fluorescence+observation+cell+binding+assay+ca1128+0502/10__1016_slash_s1474___4422_ascii40_24_ascii41_00077___2-81-29-30
Average 90 stars, based on 1 article reviews
visual fluorescence-observation cell-binding assay ca1128-0502 - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
Fluorescence:Article Title: Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder Article Snippet: The assay will be conducted by a central laboratory using a commercially available Article Title: Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial Article Snippet: The assay will be conducted by a central laboratory using a commercially available Cell Binding Assay:Article Title: Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder Article Snippet: The assay will be conducted by a central laboratory using a commercially available Article Title: Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial Article Snippet: The assay will be conducted by a central laboratory using a commercially available |